IGHE and asthma: By targeting the Fc fragment of IgE, Omalizumab, an anti-IgE monoclonal antibody, reduces free serum IgE levels and inhibits the binding of IgE to its high-affinity receptors on mast cells and basophils for the treatment of asthma.